Improved hepatitis C screening and treatment in people who inject drugs should be a priority in Europe.
作者信息
Kautz Achim, Chavdarova Lilyana, Walker Margaret
出版信息
BMC Infect Dis. 2014;14 Suppl 6(Suppl 6):S3. doi: 10.1186/1471-2334-14-S6-S3. Epub 2014 Sep 19.
Abstract
摘要
相似文献
1
Improved hepatitis C screening and treatment in people who inject drugs should be a priority in Europe.改善对注射吸毒者的丙型肝炎筛查和治疗应成为欧洲的一项优先事项。
BMC Infect Dis. 2014;14 Suppl 6(Suppl 6):S3. doi: 10.1186/1471-2334-14-S6-S3. Epub 2014 Sep 19.
2
Eradication of hepatitis C infection: the importance of targeting people who inject drugs.丙型肝炎感染的消除：针对注射吸毒者的重要性。
Hepatology. 2014 Feb;59(2):366-9. doi: 10.1002/hep.26623. Epub 2013 Dec 24.
3
A national multidisciplinary healthcare network for treatment of hepatitis C in people who inject drugs in Slovenia.斯洛文尼亚一个用于治疗注射吸毒者丙型肝炎的全国多学科医疗保健网络。
BMC Infect Dis. 2014;14 Suppl 6(Suppl 6):S6. doi: 10.1186/1471-2334-14-S6-S6. Epub 2014 Sep 19.
4
Expanding access to prevention, care and treatment for hepatitis C virus infection among people who inject drugs.扩大注射吸毒者获得丙型肝炎病毒感染预防、护理和治疗的机会。
Int J Drug Policy. 2015 Oct;26(10):893-8. doi: 10.1016/j.drugpo.2015.07.007. Epub 2015 Jul 17.
5
Access to hepatitis C care for people who inject drugs and people in prisons.为注射吸毒者和监狱服刑人员提供丙型肝炎治疗服务。
Lancet Gastroenterol Hepatol. 2019 Sep;4(9):662-663. doi: 10.1016/S2468-1253(19)30201-8. Epub 2019 Jul 27.
6
Restrictions on access to direct-acting antivirals for people who inject drugs: The European Hep-CORE study and the role of patient groups in monitoring national HCV responses.对注射吸毒者获取直接作用抗病毒药物的限制：欧洲Hep-CORE研究及患者群体在监测各国丙型肝炎应对措施中的作用。
Int J Drug Policy. 2017 Sep;47:47-50. doi: 10.1016/j.drugpo.2017.05.054. Epub 2017 Jul 6.
7
Who: four ways to reduce hepatitis infections in people who inject drugs.谁：减少注射毒品者感染肝炎的四种方法。
Cent Eur J Public Health. 2012 Sep;20(3):207.
8
Hepatitis - a devastating epidemic in Europe.肝炎——欧洲一场毁灭性的流行病。
BMC Infect Dis. 2014;14 Suppl 6(Suppl 6):S1. doi: 10.1186/1471-2334-14-S6-S1. Epub 2014 Sep 19.
9
Policy responses to viral hepatitis B and C among people who inject drugs in Member States of the WHO European region: a sub-analysis of the WHO 2013 global hepatitis policy survey.世界卫生组织欧洲区域成员国中注射吸毒者对乙型和丙型病毒性肝炎的政策应对：世卫组织2013年全球肝炎政策调查的子分析
BMC Infect Dis. 2014;14 Suppl 6(Suppl 6):S15. doi: 10.1186/1471-2334-14-S6-S15. Epub 2014 Sep 19.
10
Eliminating hepatitis C: The importance of frequent testing of people who inject drugs in high-prevalence settings.消除丙型肝炎：在高流行地区对注射毒品人群进行频繁检测的重要性。
J Viral Hepat. 2018 Dec;25(12):1472-1480. doi: 10.1111/jvh.12975. Epub 2018 Aug 28.
引用本文的文献
1
State of the Art, Unresolved Issues, and Future Research Directions in the Fight against Hepatitis C Virus: Perspectives for Screening, Diagnostics of Resistances, and Immunization.抗击丙型肝炎病毒的现状、未解决的问题及未来研究方向：筛查、耐药性诊断和免疫的前景
J Immunol Res. 2016;2016:1412840. doi: 10.1155/2016/1412840. Epub 2016 Oct 24.
本文引用的文献
1
Infection with hepatitis B and C virus in Europe: a systematic review of prevalence and cost-effectiveness of screening.在欧洲，乙型肝炎和丙型肝炎病毒感染：筛查的流行率和成本效益的系统评价。
BMC Infect Dis. 2013 Apr 18;13:181. doi: 10.1186/1471-2334-13-181.
2
The burden of liver disease in Europe: a review of available epidemiological data.欧洲的肝脏疾病负担：现有流行病学数据综述。
J Hepatol. 2013 Mar;58(3):593-608. doi: 10.1016/j.jhep.2012.12.005.
3
EMCDDA publishes guidelines on testing for HIV, viral hepatitis and other infections in injecting drug users.欧洲毒品和药物成瘾监测中心发布了关于对注射吸毒者进行艾滋病毒、病毒性肝炎及其他感染检测的指南。
Euro Surveill. 2010 Dec 2;15(48):19735. doi: 10.2807/ese.15.48.19735-en.
4
The impact of the prevention programme of hepatitis C over more than a decade: the French experience.超过十年的丙型肝炎预防计划的影响：法国经验。
J Viral Hepat. 2010 Jun;17(6):435-43. doi: 10.1111/j.1365-2893.2009.01196.x. Epub 2009 Sep 23.
Zotero 插件